510
Participants
Start Date
October 28, 2018
Primary Completion Date
March 26, 2024
Study Completion Date
March 26, 2024
Celestamine®
Children in KIDS-STEP will be receiving either oral betamethasone (Celestamine®) or oral placebo dosed once daily for two consecutive days. Celestamine® N 0.5 liquidum is a betamethasone solution and will be used in the active comparator arm. Study medication will be administered orally once a day on two consecutive days. A standard dose of 0.1-0.2 mg/kg will be used. All doses used in KIDS-STEP fall into the range of recommended doses according to the Summary of Medical Product Characteristics.
Centre hospitalier universitaire vaudois, Lausanne
Geneva University Hospital, Department of Pediatrics, Geneva
Kantonsspital- Freiburger Spital (HFR), Villars-sur-Glâne
Inselspital Bern, Bern
University of Basel Children's Hospital (UKBB), Basel
Kantonsspital Aarau, Klinik für Kinder u. Jugendliche, Aarau
Luzerner Kantonsspital, Kinderspital, Lucerne
University-Childrens Hospital Zürich, Zurich
Ostschweizer Kinderspital, Sankt Gallen
Universitätsklinikum der Ruhr-Universität Bochum, Klinik für Kinder- und Jugendmedizin, Bochum
Universitätsklinikum Düsseldorf, Klinik für Allgemeine Pädiatrie, Düsseldorf
Universitätsklinikum Freiburg, Zentrum für Kinder und Jugendmedizin Freiburg, Freiburg im Breisgau
Universitätsklinikum Tübingen, Klinik für Kinder- und Jugendmedizin, Tübingen
Swiss National Fund for Scientific Research
OTHER
University Hospital, Basel, Switzerland
OTHER
SwissPedNet
UNKNOWN
Julia Bielicki
OTHER